中低收入国家的主动疫苗安全监测:新兴国家疫苗制造商面临的挑战
发展中国家疫苗制造商网络(DCVMN)总结中低收入国家(LMIC)主动疫苗安全监测(AVSS)的实施挑战。传统上LMIC依赖被动监测,但资源有限地区被动监测不足,AVSS可通过哨点或观察性研究补充。COVID-19期间新疫苗快速引入加速了AVSS需求,国家监管机构和WHO预认证团队要求风险管理计划,企业承诺或监管机构强制开展AVSS。DCVMN开展「边做边学」项目以支持制造商,并探讨支持需求、机会、挑战与障碍及解决方案。
要点
- LMIC传统疫苗安全监测依赖自发报告,资源有限地区被动监测不足。
- AVSS可通过哨点主动收集不良事件或设计观察性研究来补充被动监测。
- COVID-19新疫苗快速引入加速LMIC对全面AVSS的需求。
核心结论
- DCVMN的「边做边学」项目聚焦于提升对AVSS及其工具的理解,调查LMIC开展AVSS的支持需求、机会、挑战与障碍,并提出可缓解主要挑战的解决方案。
研究设计与样本
- DCVMN发起「边做边学」项目,以支持制造商/上市许可持有人开展AVSS。
主要发现
- LMIC传统疫苗安全监测依赖自发报告,但资源有限地区缺乏稳健的被动监测。
- AVSS可通过哨点主动收集不良事件或通过正式设计的观察性(非干预性)研究补充被动监测。
- COVID-19疫情期间新疫苗快速引入且部署时安全信息有限,加速了LMIC对全面AVSS的需求。
- 国家监管机构和WHO预认证团队要求提交符合药物警戒规划指南的风险管理计划(RMP),其中包含上市后常规被动监测和额外主动监测活动的承诺。
- AVSS活动由制造商/上市许可持有人自愿承诺,或在重要已识别/潜在风险或重要缺失信息时由国家监管机构/WHO预认证强制要求。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Developing Countries Vaccine Manufacturers Network (DCVMN) is an alliance of vaccine developers, manufacturers, and marketing authorization holders (MAHs) from low- and middle-income countries (LMICs) that plays a vital role in ensuring equitable, inclusive, accountable, and timely access to affordable, high-quality vaccines in these countries. Besides research and development, this network promotes manufacturing and global supply chains for effective strengthening of regulatory and pharmacovigilance activities. Traditionally, vaccine safety surveillance systems in LMICs rely on spontaneous reporting. However, especially in resource-limited settings, robust passive surveillance is lacking, and active vaccine safety surveillance (AVSS) can complement passive surveillance by actively collecting adverse events at sentinel sites or via formally designed observational (non-interventional) studies. The rapid introduction of novel vaccines during the COVID-19 pandemic with rather limited safety information at deployment accelerated the need for comprehensive AVSS in LMICs to detect potential safety concerns that may not have been identified in pre-licensure trials. In this context, national regulatory agencies (NRAs) and the World Health Organization (WHO) prequalification team requested risk management plans (RMPs) in line with Pharmacovigilance Planning guideline. The submitted RMPs contained the companies' commitments to pharmacovigilance activities encompassing both post-approval routine surveillance (passive) and additional active surveillance activities. These AVSS activities were either committed voluntarily by the manufacturers/MAHs or imposed by the NRA/WHO prequalification in case of important identified or potential risks, or important missing information. Unlike passive surveillance, AVSS relies on various epidemiological methodologies that require resources and expertise. DCVMN initiated a "learn-by-doing" project to support manufacturers/MAHs in performing AVSS. This project focused on improving the understanding of AVSS and its tools, investigated the support needs, opportunities, challenges, and barriers to performing AVSS activities in LMICs, and proposed solutions that could be used to mitigate the main challenges in performing AVSS activities in these countries.
引用
- de Oliveira PMN, Hartmann K, Bhamare C, et al. Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries. Vaccine. 2025. PMID: 39813974. doi:10.1016/j.vaccine.2025.126727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。